A biopharmaceutical company.

ARYx Therapeutics to complete an out-licensing contract for clinical commercialization and advancement of budiodarone ARYx Therapeutics, Inc. , a biopharmaceutical company, today announced that it has implemented a staffing plan to operate the business that anticipates licensing its lead development applications and resuming advancement of earlier stage item applicants. ARYx expects to complete an out-licensing agreement in the near term for the clinical development and commercialization of its oral anti-arrythmic agent, budiodarone, and, following that, getting into similar agreements for its two other past due stage items, ATI-7505, for the treating numerous gastrointestinal disorders, and tecarfarin, an oral anticoagulant agent sildenafil citrate .